PT-141 Overview

PT-141, also known as Bremelanotide, is a synthetic peptide primarily developed for treating sexual dysfunction. Unlike traditional treatments that focus on the vascular system, PT-141 targets the nervous system by activating melanocortin receptors, particularly MC3R and MC4R. This unique mechanism has shown effectiveness in addressing both male erectile dysfunction (ED) and female sexual arousal disorder (FSAD), making PT-141 a promising alternative for enhancing sexual desire and satisfaction.

Product Details

• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• Molecular Formula: C50H68N14O10
• Molecular Weight: 1025.2 g/mol
• PubChem CID: 9941370
• CAS Number: 189691-06-3

Research Highlights

1. Effective Treatment for Female Sexual Arousal Disorder (FSAD): PT-141 has demonstrated significant potential in clinical trials for treating FSAD. By stimulating melanocortin receptors, it increases sexual desire and arousal without relying on hormonal pathways, offering a novel solution for women experiencing low sexual desire.
2. Alternative Approach to Erectile Dysfunction (ED): PT-141 has been explored as a treatment for ED in men, functioning through the central nervous system rather than the vascular system. This provides a different therapeutic option for men who do not respond to or cannot use traditional ED medications like sildenafil.
3. Non-Hormonal Mechanism of Action: PT-141 works directly on the nervous system, bypassing the hormonal routes often associated with sexual dysfunction treatments. This makes it a valuable option for individuals seeking non-hormonal therapies.
4. Extensive Clinical Validation: PT-141 has undergone numerous clinical trials, demonstrating its efficacy in enhancing sexual desire and arousal in both men and women. It is well-tolerated, with a favorable safety profile and minimal side effects.